Extrait

Phase I: 1) To assess the MTD and monitor the safety of L19IL2 in combination with Rituximab in patients with relapsed or refractory DLBCL and to describe DLT. 2) To define the RD of L19IL2 to be used in phase II when administered in combination with Rituximab to patients with relapsed or refractory DLBCL. Phase II: To assess the therapeutic efficacy measured as complete remission rate and ORR of L19IL2 when administered in combination with Rituximab to patients with relapsed or refractory DLBCL.

Critère d'inclusion

• Relapsed or refractory CD20+ diffuse large B-cell lymphoma (DLBCL) in patients who are ineligible for autologous stem cell transplantation or who relapse/progress after transplantation

Liens

• euctr